61-72-3 Usage
Uses
Used in Pharmaceutical Industry:
Cloxacillin is used as an antibacterial agent for the treatment of various bacterial infections caused by susceptible strains of gram-positive bacteria. It is particularly effective against methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant strains. Cloxacillin works by inhibiting bacterial cell wall synthesis, leading to cell lysis and death.
In addition to its primary use as an antibacterial agent, cloxacillin may also be used in combination with other medications or therapies to enhance their effectiveness or to treat specific conditions. However, it is essential to consult a healthcare professional before using cloxacillin in combination with other medications to ensure safety and effectiveness.
Therapeutic Function
Antibacterial
World Health Organization (WHO)
Ampicillin and cloxacillin are listed separately in the WHO Model
List of Essential Drugs.
Contact allergens
Cloxacillin is a semisynthetic penicillin close to oxacillin.
It induced contact dermatitis in a pharmaceutical
factory worker with positive reactions to ampicillin,
but not to penicillin. In cutaneous drug reactions such
as acute generalized exanthematous pustulosis due to
amoxicillin, cross-reactivity is frequent to cloxacillin
(personal observations).
Purification Methods
Purify mandelic acid by Soxhlet extraction with *C6H6 (about 6mL/g) and allow the extract to crystallise. It can also be recrystallised from CHCl3. The S-benzylisothiuronium salt has m 169o (166o) (from H2O). Dry it at room temperature under vacuum. [Beilstein 10 IV 565.]
Check Digit Verification of cas no
The CAS Registry Mumber 61-72-3 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 6 and 1 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 61-72:
(4*6)+(3*1)+(2*7)+(1*2)=43
43 % 10 = 3
So 61-72-3 is a valid CAS Registry Number.
InChI:InChI=1/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1
61-72-3Relevant academic research and scientific papers
LIQUID PHARMACEUTICAL FOR ORAL DELIVERY
-
, (2008/06/13)
A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.
Method of using deuterated calcium channel blockers
-
, (2008/06/13)
Therapeutic methods and compositions using deuterated enriched 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester and other deuterated dihydropyridine compounds are described. The deuterated compounds exhibit enhanced efficacy in blocking calcium channels over non-deuterated dihydropyridines.
Enhancement of the efficacy of nifedipine by deuteration
-
, (2008/06/13)
A method of enhancing the efficiency and increasing the duration of action of drugs (e.g. dihydropyridines and anti-bacterials) and particularly of nifedipine and penicillins wherein one or more hydrogen atoms are deuterated and wherein the deuterated drug has unexpectedly improved properties when used in much lower concentrations than unmodified drug. A method for determining the identity and bioequivalency of a new drug is also disclosed wherein the molecular and isotope structure of a new drug is determined by isotope ratio mass spectrometry and compared with the molecular and isotope structure of a known human drug.
